Novartis announces US FDA approval of Xolair® for chronic idiopathic urticaria
- Details
- Category: Novartis
Novartis announced that the US Food and Drug Administration (FDA) has approved Xolair® (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), an unpredictable and debilitating skin disease that is known as chronic spontaneous urticaria (CSU) outside of the US. In the US, Xolair is indicated for CIU in adults and adolescents (12 years of age and above) who remain symptomatic despite H1-antihistamine treatment[5].
Bayer to invest more than 500 million Euros for the manufacturing of hemophilia A products currently in development
- Details
- Category: Bayer
With an investment of more than 500 million Euros at its sites in Wuppertal and Leverkusen, Germany, Bayer will establish additional capacities for the manufacturing of the recombinant factor VIII (rFVIII) hemophilia products that are currently in development. The investigational therapy options for hemophilia patients - a plasma protein-free rFVIII (BAY 81-8973) and a long-acting rFVIII (BAY 94-9027) - are both currently in Phase III clinical trials.
Five Prime Therapeutics and Bristol-Myers Squibb sign collaboration agreement
- Details
- Category: Bristol-Myers Squibb
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) and Bristol-Myers Squibb Company (NYSE:BMY) have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime's proprietary target discovery platform.
Sanofi and UCB partner for breakthrough innovation in immune-mediated diseases
- Details
- Category: Sanofi
Sanofi (EURONEXT : SAN and NYSE : SNY) and UCB have entered into a scientific and strategic collaboration for the discovery and development of innovative anti-inflammatory small molecules, which have the potential to treat a wide range of immune-mediated diseases in areas such as gastroenterology and arthritis.
GSK increases stake in Indian Pharmaceuticals subsidiary to 75 %
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (LSE:GSK) announced that, following the voluntary Open Offer undertaken by its subsidiary, GlaxoSmithKline Pte Ltd, GSK has successfully increased its stake in its publicly-listed pharmaceuticals subsidiary in India (GlaxoSmithKline Pharmaceuticals Limited), from 50.7% to 75%. GlaxoSmithKline Pharmaceuticals Limited will remain publicly-listed.
Pradaxa® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation
- Details
- Category: Boehringer Ingelheim
More than 100 countries have now approved Boehringer Ingelheim's Pradaxa® for the prevention of stroke and systemic embolism for adult patients with the most common sustained heart rhythm condition (non-valvular atrial fibrillation, nvAF).(1) The 100th approval was announced by the Jordan Food and Drug Administration. Further regulatory approvals for Pradaxa® are expected to be received in the near future.
Bristol-Myers Squibb announces charitable donation of $1 million
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company today announced donations totaling $1 million in 2013 to four nonprofit organizations that support patients with cancer. The donations will fund the development and availability of educational materials for patients and caregivers about the emerging field of cancer research and treatment called immuno-oncology.
More Pharma News ...
- Novartis extends leadership in clinical trial data transparency
- Eliquis® (apixaban) reduced the risk of stroke and demonstrated fewer major bleeding events versus Warfarin
- Boehringer Ingelheim receives East Bay Innovation Award
- Novartis expands cancer immunotherapy research program with acquisition of CoStim
- Crystal Bioscience and Boehringer Ingelheim announce multiple target antibody discovery collaboration
- Pfizer and Merck to collaborate on innovative anti-cancer combination studies
- Amgen and Merck announce collaboration To evaluate investigational combination treatment for advanced melanoma